In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:
the following entries are inserted:
Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATE | Notes
Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)
‘601-093-00-6 | 1,4-dimethylnaphthalene | 209-335-9 | 571-58-4 |
Acute Tox. 4
Asp. Tox. 1
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 3
H302
H304
H319
H400
H412
GHS07
GHS08
GHS09
Dgr
H302
H304
H319
H410
oral: ATE = 1300 mg/kg bw
M = 1’
‘601-094-00-1 |
1-isopropyl-4-methylbenzene;
p-cymene
202-796-7 | 99-87-6 |
Flam. Liq. 3
Acute Tox. 3
Asp. Tox. 1
Aquatic Chronic 2
H226
H331
H304
H411
GHS02
GHS06
GHS08
GHS09
Dgr
H226
H331
H304
H411
inhalation: ATE = 3 mg/l (vapours)’ |
‘601-095-00-7 |
p-mentha-1,3-diene; 1-isopropyl-4-methylcyclohexa-1,3-diene;
alpha-terpinene
202-795-1 | 99-86-5 |
Flam. Liq. 3
Acute Tox. 4
Skin Sens. 1
Asp. Tox. 1
Aquatic Chronic 2
H226
H302
H317
H304
H411
GHS02
GHS07
GHS08
GHS09
Dgr
H226
H302
H317
H304
H411
oral: ATE = 1680 mg/kg bw’ |
‘602-110-00-X | tetrafluoroethylene | 204-126-9 | 116-14-3 | Carc. 1B | H350 |
GHS08
Dgr
H350’ | | |
‘604-095-00-5 |
6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol;
[DBMC]
204-327-1 | 119-47-1 | Repr. 1B | H360F |
GHS08
Dgr
H360F’ | | |
‘606-152-00-X | (5-chloro-2-methoxy-4-methyl-3-pyridyl)(4,5,6-trimethoxy-o-tolyl)methanone; pyriofenone | - | 688046-61-9 |
Carc. 2
Aquatic Chronic 1
H351
H410
GHS08
GHS09
Wng
H351
H410
M = 1’ |
‘607-747-00-7 | 2,2-dibromo-2-cyanoacetamide; [DBNPA] | 233-539-7 | 10222-01-2 |
Acute Tox. 2
Acute Tox. 3
STOT RE 1
Skin Irrit. 2
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H330
H301
H372 (respiratory tract) (inhalation)
H315
H318
H317
H400
H410
GHS06
GHS08
GHS05
GHS09
Dgr
H330
H301
H372 (respiratory tract) (inhalation)
H315
H318
H317
H410
inhalation: ATE = 0,24 mg/l (dusts or mists)
oral: ATE = 118 mg/kg bw
M = 1
M = 1’
‘607-748-00-2 |
[S-(Z,E)]-5-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)-3-methylpenta-2,4-dienoic acid;
S-abscisic acid
244-319-5 | 21293-29-8 |
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 | |
M = 1
M = 1’
‘607-749-00-8 | methyl salicylate | 204-317-7 | 119-36-8 |
Repr. 2
Acute Tox. 4
Skin Sens. 1B
Aquatic Chronic 3
H361d
H302
H317
H412
GHS07
GHS08
Wng
H361d
H302
H317
H412
oral: ATE = 890 mg/kg bw’ |
‘607-750-00-3 | citric acid | 201-069-1 | 77-92-9 |
Eye Irrit. 2
STOT SE 3
H319
H335
GHS07
Wng
H319
H335’
‘607-751-00-9 |
ethametsulfuron-methyl (ISO);
methyl 2-({[4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)benzoate
| 97780-06-8 |
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H319
H400
H410
GHS07
GHS09
Wng
H319
H410
M = 1000
M = 100’
‘607-752-00-4 |
trinexapac-ethyl (ISO);
ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate
| 95266-40-3 |
STOT RE 2
Skin Sens. 1B
Aquatic Chronic 1
H373 (gastrointestinal tract)
H317
H410
GHS08
GHS07
GHS09
Wng
H373 (gastrointestinal tract)
H317
H410
M = 1’ |
‘607-753-00-X | (3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide | - | 78821-43-9 | Aquatic Chronic 4 | H413 | | H413’ | | |
‘607-754-00-5 | benzyl salicylate | 204-262-9 | 118-58-1 | Skin Sens. 1B | H317 |
GHS07
Wng
H317’ | | |
‘607-755-00-0 |
(RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate;
tolpyralate
| 1101132-67-5 |
Carc. 2
Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H361fd
H373 (eye)
H400
H410
GHS08
GHS09
Wng
H351
H361fd
H373 (eye)
H410
M = 10
M = 100’
‘613-337-00-9 |
prothioconazole (ISO);
2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione
| 178928-70-6 |
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 | |
M = 10
M = 1’
‘613-338-00-4 | azamethiphos (ISO); S-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl] O,O-dimethyl thiophosphate | 252-626-0 | 35575-96-3 |
Carc. 2
Acute Tox. 3
Acute Tox. 4
STOT SE 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H331
H302
H370 (nervous system)
H317
H400
H410
GHS06
GHS08
GHS09
Dgr
H351
H331
H302
H370 (nervous system)
H317
H410
inhalation: ATE = 0,5 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 1000
M = 1000’
‘613-339-00-X | 3-methylpyrazole | 215-925-7 | 1453-58-3 |
Repr. 1B
Acute Tox. 4
STOT RE 2
Skin Corr. 1
Eye Dam. 1
H360D
H302
H373 (lung)
H314
H318
GHS08
GHS07
GHS05
Dgr
H360D
H302
H373 (lung)
H314
oral: ATE = 500 mg/kg bw’ |
‘613-340-00-5 | clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one | - | 81777-89-1 |
Acute Tox. 4
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H400
H410
GHS07
GHS09
Wng
H332
H302
H410
inhalation: ATE = 4,85 mg/l (dusts or mists)
oral: ATE = 768 mg/kg bw
M = 1
M = 1’
‘614-030-00-2 | emamectin benzoate (ISO); (4"R)-4"-deoxy-4"-(methylamino) avermectin B1 benzoate | - | 155569-91-8 |
Acute Tox. 3
Acute Tox. 3
Acute Tox. 3
STOT SE 1
STOT RE 1
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H331
H311
H301
H370 (nervous system)
H372 (nervous system)
H318
H400
H410
GHS06
GHS05
GHS08
GHS09
Dgr
H331
H311
H301
H370 (nervous system)
H372 (nervous system)
H318
H410
inhalation:
ATE = 0,663
mg/l (dusts or mists)
dermal:
ATE = 300
mg/kg bw
oral: ATE =
60 mg/kg bw
STOT RE 1; H372: C ≥ 5 %; STOT RE 2; H373: 0,5 % ≤ C < 5 %
M = 10000
M = 10000’
‘616-234-00-7 | N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen | - | 1228284-64-7 |
Carc. 2
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H361f
H400
H410
GHS08
GHS09
Wng
H351
H361f
H410
M = 1
M = 1’
‘616-235-00-2 | N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane | - | 874967-67-6 |
Carc. 2
Aquatic Acute 1
Aquatic Chronic 2
H351
H400
H411
GHS08
GHS09
Wng
H351
H410
M = 1’ |
the entries corresponding to index numbers 005-007-00-2; 005-008-00-8; 005-011-00-4; 005-011-01-1; 005-011-02-9; 006-069-00-3; 006-076-00-1; 015-113-00-0; 028-007-00-4; 029-002-00-X; 029-015-00-0; 029-016-00-6; 029-017-00-1; 029-018-00-7; 029-019-01-X; 029-020-00-8; 029-021-00-3; 029-022-00-9; 029-023-00-4; 601-029-00-7; 601-096-00-2; 603-024-00-5; 603-066-00-4; 603-098-00-9; 606-004-00-4; 607-421-00-4; 607-424-00-0; 607-434-00-5; 608-058-00-4; 612-067-00-9; 612-252-00-4; 613-048-00-8; 613-102-00-0; 613-111-00-X; 613-166-00-X; 613-208-00-7; 613-267-00-9; 613-282-00-0; 616-032-00-9; 616-106-00-0 and 616-113-00-9 are replaced by the following entries respectively:
Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M- factors and ATE | Notes
Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)
‘005-007-00-2 |
boric acid [1]
boric acid [2]
233-139-2 [1]
234-343-4 [2]
10043-35-3 [1]
11113-50-1 [2]
Repr. 1B | H360FD |
GHS08
Dgr
H360FD’ | | |
‘005-008-00-8 | diboron trioxide | 215-125-8 | 1303-86-2 | Repr. 1B | H360FD |
GHS08
Dgr
H360FD’ | | |
‘005-011-00-4 |
tetraboron disodium heptaoxide, hydrate; [1]
disodium tetraborate, anhydrous; [2]
orthoboric acid, sodium salt [3]
disodium tetraborate decahydrate [4]
disodium tetraborate pentahydrate [5]
235-541-3 [1]
215-540-4 [2]
237-560-2 [3]
215-540-4 [4]
215-540-4 [5]
12267-73-1 [1]
1330-43-4 [2]
13840-56-7 [3]
1303-96-4 [4]
12179-04-3 [5]
Repr. 1B | H360FD |
GHS08
Dgr
H360FD’ | | |
‘006-069-00-3 |
thiophanate-methyl (ISO);
dimethyl (1,2-phenylenedicarbamothioyl)biscarbamate;
dimethyl 4,4′-(o-phenylene)bis(3-thioallophanate)
245-740-7 | 23564-05-8 |
Carc. 2
Muta. 2
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H341
H332
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H341
H332
H317
H410
inhalation: ATE = 1,7 mg/l
(dusts and mists)
M = 10
M = 10’
‘006-076-00-1 | mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt | - | 8018-01-7 |
Carc. 2
Repr. 1B
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H360D
H373 (thyroid, nervous system)
H317
H400
H410
GHS08
GHS07
GHS09
Dgr
H351
H360D
H373 (thyroid, nervous system)
H317
H410
M = 10
M = 10’
‘015-113-00-0 |
tolclofos-methyl (ISO);
O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate
260-515-3 | 57018-04-9 |
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1
H317
H400
H410
GHS07
GHS09
Wng
H317
H410
M = 1
M = 1’
‘028-007-00-4 |
trinickel disulfide;
nickel subsulfide; [1]
heazlewoodite [2]
234-829-6 [1]
[2]
12035-72-2 [1]
12035-71-1 [2]
Carc. 1A
Muta. 2
Acute Tox. 3
STOT RE 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H350i
H341
H331
H372**
H317
H400
H410
GHS08
GHS06
GHS09
Dgr
H350i
H341
H331
H372**
H317
H410
inhalation:
ATE = 0,92 mg/l
(dusts or mists)’
‘029-002-00-X |
dicopper oxide;
copper (I) oxide
215-270-7 | 1317-39-1 |
Acute Tox. 4
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H332
H302
H318
H410
inhalation: ATE = 3,34 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 100
M = 10’
‘029-015-00-0 | copper thiocyanate | 214-183-1 | 1111-67-7 |
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 | EUH032 |
M = 10
M = 10’
‘029-016-00-6 | copper(II) oxide | 215-269-1 | 1317-38-0 |
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 | |
M = 100
M = 10’
‘029-017-00-1 | dicopper chloride trihydroxide | 215-572-9 | 1332-65-6 |
Acute Tox. 4
Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1
H332
H301
H400
H410
GHS06
GHS09
Dgr
H332
H301
H410
inhalation: ATE = 2,83 mg/l (dusts or mists)
oral: ATE = 299 mg/kg bw
M = 10
M = 10’
‘029-018-00-7 |
tetracopper hexahydroxide sulphate; [1]
tetracopper hexahydroxide sulphate hydrate [2]
215-582-3 [1]
215-582-3 [2]
1333-22-8 [1]
12527-76-3 [2]
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H302
H400
H410
GHS07
GHS09
Wng
H302
H410
oral: ATE = 500 mg/kg bw
M = 10
M = 10’
‘029-019-01-X | copper flakes (coated with aliphatic acid) | - | - |
Acute Tox. 3
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H331
H302
H319
H400
H410
GHS06
GHS09
Dgr
H331
H302
H319
H410
inhalation: ATE = 0,733 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 10’
‘029-020-00-8 | copper(II) carbonate—copper(II) hydroxide (1:1) | 235-113-6 | 12069-69-1 |
Acute Tox. 4
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H319
H400
H410
GHS07
GHS09
Wng
H332
H302
H319
H410
inhalation: ATE = 1,2 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 10’
‘029-021-00-3 |
copper dihydroxide;
copper(II) hydroxide
243-815-9 | 20427-59-2 |
Acute Tox. 2
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H330
H302
H318
H400
H410
GHS06
GHS05
GHS09
Dgr
H330
H302
H318
H410
inhalation: ATE = 0,47 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 10’
‘029-022-00-9 |
bordeaux mixture;
reaction products of copper sulphate with calcium dihydroxide
| 8011-63-0 |
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H332
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H332
H318
H410
inhalation: ATE = 1,97 mg/l (dusts or mists)
M = 10
M = 1’
‘029-023-00-4 | copper sulphate pentahydrate | 231-847-6 | 7758-99-8 |
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H302
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H302
H318
H410
oral: ATE = 481 mg/kg bw
M = 10
M = 1’
‘601-029-00-7 |
dipentene;
limonene [1]
(S)-p-mentha-1,8-diene; l-limonene [2]
trans-1-methyl-4-(1-methylvinyl)cyclohexene; [3]
(±)-1-methyl-4-(1-methylvinyl)cyclohexene [4]
205-341-0 [1]
227-815-6 [2]
229-977-3 [3]
231-732-0 [4]
138-86-3 [1]
5989-54-8 [2]
6876-12-6 [3]
7705-14-8 [4]
Flam. Liq. 3
Skin Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H226
H315
H317
H400
H410
GHS02
GHS07
GHS09
Wng
H226
H315
H317
H410
C’
‘601-096-00-2 |
(R)-p-mentha-1,8-diene;
d-limonene
227-813-5 | 5989-27-5 |
Flam. Liq. 3
Skin Irrit. 2
Skin Sens. 1B
Asp. Tox. 1
Aquatic Acute 1
Aquatic Chronic 3
H226
H315
H317
H304
H400
H412
GHS02
GHS07
GHS08
GHS09
Dgr
H226
H315
H317
H304
H410
M = 1’ |
‘603-024-00-5 | 1,4-dioxane | 204-661-8 | 123-91-1 |
Flam. Liq. 2
Carc. 1B
STOT SE 3
Eye Irrit. 2
H225
H350
H335
H319
GHS02
GHS08
GHS07
Dgr
H225
H350
H335
H319
EUH019
EUH066
D’
‘603-066-00-4 | 7-oxa-3-oxiranylbicyclo[4.1.0]heptane; 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide | 203-437-7 | 106-87-6 |
Carc. 1B
Muta. 2
Repr. 1B
Acute Tox. 3
Acute Tox. 4
H350
H341
H360F
H331
H302
GHS08
GHS06
Dgr
H350
H341
H360F
H331
H302
inhalation: ATE = 0,5 mg/l (dusts or mists)
oral: ATE = 1847 mg/kg bw’
‘603-098-00-9 | 2-phenoxyethanol | 204-589-7 | 122-99-6 |
Acute Tox. 4
STOT SE 3
Eye Dam. 1
H302
H335
H318
GHS05
GHS07
Dgr
H302
H335
H318
oral:
ATE = 1394 mg/kg bw’
‘606-004-00-4 | 4-methylpentan-2-one; isobutyl methyl ketone | 203-550-1 | 108-10-1 |
Flam. Liq. 2
Carc. 2
Acute Tox. 4
STOT SE 3
Eye Irrit. 2
H225
H351
H332
H336
H319
GHS02
GHS07
GHS08
Dgr
H225
H351
H332
H336
H319
EUH066 | inhalation: ATE = 11 mg/l (vapours)’ |
‘607-421-00-4 |
cypermethrin (ISO);
α-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; cypermethrin cis/trans +/- 40/60
257-842-9 | 52315-07-8 |
Acute Tox. 4
Acute Tox. 4
STOT SE 3
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H335
H373 (nervous system)
H400
H410
GHS07
GHS08
GHS09
Wng
H332
H302
H335
H373 (nervous system)
H410
oral; ATE = 500 mg/kg bw
inhalation; ATE = 3,3 mg/l (dusts or mists)
M = 100000
M = 100000’
‘607-424-00-0 | trifloxystrobin (ISO); methyl (E)-methoxyimino-{(E)-α-[1-(α,α,α-trifluoro-m-tolyl)ethylideneaminooxy]-o-tolyl}acetate | - | 141517-21-7 |
Lact.
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H362
H317
H400
H410
GHS07
GHS09
Wng
H362
H317
H410
M = 100
M = 10’
‘607-434-00-5 |
mecoprop-P (ISO) [1] and its salts;
(R)-2-(4-chloro-2-methylphenoxy)propionic acid [1] and its salts
240-539-0 [1] | 16484-77-8 [1] |
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H302
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H302
H318
H410
oral: ATE = 431 mg/kg bw
M = 10
M = 10’
‘608-058-00-4 |
esfenvalerate (ISO);
(S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate
| 66230-04-4 |
Acute Tox. 3
Acute Tox. 3
STOT SE 1
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H331
H301
H370 (nervous system)
H373
H317
H400
H410
GHS06
GHS08
GHS09
Dgr
H331
H301
H370 (nervous system)
H373
H317
H410
oral; ATE = 88,5 mg/kg bw
inhalation; ATE = 0,53 mg/l (dusts or mists)
M = 10000
M = 10000’
‘612-067-00-9 | 3-aminomethyl-3,5,5-trimethylcyclohexylamine | 220-666-8 | 2855-13-2 |
Acute Tox. 4
Skin Corr. 1B
Eye Dam. 1
Skin Sens. 1A
H302
H314
H318
H317
GHS05
GHS07
Dgr
H302
H314
H317
oral: ATE = 1030 mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,001 %’
‘612-252-00-4 |
imidacloprid (ISO);
(E)-1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolidin-2-ylideneamine;
(2E)-1-[(6-chloropyridin-3-yl) methyl]-N-nitroimidazolidin-2-imine
428-040-8 | 138261-41-3 |
Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1
H301
H400
H410
GHS06
GHS09
Dgr
H301
H410
oral: ATE = 131 mg/kg bw
M = 100
M = 1000’
‘613-048-00-8 | carbendazim (ISO); methyl benzimidazol-2-ylcarbamate | 234-232-0 | 10605-21-7 |
Muta. 1B
Repr. 1B
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H340
H360FD
H317
H400
H410
GHS07
GHS08
GHS09
Dgr
H340
H360FD
H317
H410
M = 10
M = 10’
‘613-102-00-0 | dimethomorph (ISO); (E,Z)-4-(3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)acryloyl)morpholine | 404-200-2 | 110488-70-5 |
Repr. 1B
Aquatic Chronic 2
H360F
H411
GHS08
GHS09
Dgr
H360F
H411’
‘613-111-00-X | 1,2,4-triazole | 206-022-9 | 288-88-0 |
Repr. 1B
Acute Tox. 4
Eye Irrit. 2
H360FD
H302
H319
GHS08
GHS07
Dgr
H360FD
H302
H319
oral: ATE = 1320 mg/kg bw’ |
‘613-166-00-X |
flumioxazin (ISO);
N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)cyclohex-1-ene-1,2-dicarboximide
| 103361-09-7 |
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
H361d
H400
H410
GHS08
GHS09
Wng
H361d
H410
M = 1000
M = 1000’
‘613-208-00-7 |
imazamox (ISO);
(RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid
| 114311-32-9 |
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
H361d
H400
H410
GHS08
GHS09
Wng
H361d
H410
M = 10
M = 10’
‘613-267-00-9 |
thiamethoxam (ISO);
3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine
428-650-4 | 153719-23-4 |
Repr. 2
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H361fd
H302
H400
H410
GHS07
GHS08
GHS09
Wng
H361fd
H302
H410
oral: ATE = 780 mg/kg bw
M = 10
M = 10’
‘613-282-00-0 |
triticonazole (ISO);
(RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol
| 138182-18-0 |
Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H361f
H373
H400
H410
GHS08
GHS09
Wng
H361f
H373
H410
M = 1
M = 1’
‘616-032-00-9 |
diflufenican (ISO);
N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide; 2′,4′-difluoro-2-(α,α,α-trifluoro-m-tolyloxy) nicotinanilide
| 83164-33-4 |
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 | |
M = 10000
M = 1000’
‘616-106-00-0 | phenmedipham (ISO); methyl 3-(3-methylcarbaniloyloxy)carbanilate | 237-199-0 | 13684-63-4 |
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 | |
M = 10
M = 10’
‘616-113-00-9 |
desmedipham (ISO);
ethyl 3-phenylcarbamoyloxyphenylcarbamate
237-198-5 | 13684-56-5 |
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
H361d
H400
H410
GHS08
GHS09
Wng
H361d
H410
M = 10
M = 10’
the entry corresponding to index number 015-192-00-1 is deleted.